BioMarin completes acquisition of Alesta Therapeutics - BMRN News | RalliesBioMarin completes acquisition of Alesta Therapeutics
B
BMRN• BioMarin closes Alesta Therapeutics acquisition
- BioMarin completed its acquisition of Alesta Therapeutics on Sept. 1.
- The deal adds ALE1, an oral small-molecule candidate for hypophosphatasia, strengthening BioMarin’s skeletal conditions portfolio.
- ALE1 is in an ongoing Phase 1/2a trial in healthy volunteers and adults, evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics.
- Alesta spun out non-ALE1 assets into a new entity before closing; Alesta now operates as a wholly owned BioMarin subsidiary.
•
